[{"title": "Temporal Trends in Arrhythmia Burden Following Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy", "link": "https://www.sciencedirect.com/science/article/pii/S1071916424003038", "details": "K Roehl, M Suppah, R Arsanjani, K Siontis, J Geske\u2026 - Journal of Cardiac Failure, 2024", "abstract": "Introduction Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. Mavacamten, the first-in-class drug approved by the FDA for the treatment of HCM, has shown efficacy in improving clinical symptoms. However, the \u2026"}]
